劉博侖 老師                                                                                

聯絡電話：07-3121101轉2801 

E-Mail：kisa@kmu.edu.tw

office hour：每週二、四 15：00～17：00

職稱

教授

學歷/經歷

國立陽明大學生理學研究所博士

國立陽明大學解剖暨細胞生物研究所碩士

國立台北護理學院學士

專長領域         

解剖學

呼吸生理學

動脈硬化防治

細胞分子生理學

教學科目

生理學

解剖學

基礎心電圖

分子生物學

組織學概論

心肺解剖生理學

心肺血管疾病特論

呼吸治療研究導論

細胞生理學研究技術

論文

1.          Chen PR, Li CY, Yazal T, Chen IC, Liu PL, Chen YT, Liu CC, Lo J, Lin TC, Chang CT, Wu HE, Chen YR, Cheng WC, Chiu CC, Chen CS, Wang SC* (2024 Jul). Protective effects of nordalbergin against LPS-induced endotoxemia through inhibiting MAPK/NF-κB signaling pathway, NLRP3 inflammasome activation, and ROS production. Inflammation Research, 73, 1657-1670. (2023 JCR IF: 4.8; 52/181, 28.7% in Immunology)

2.          Cheng MH, Kuo HF, Chang CY, Chang JC, Liu IF, Hsieh CC, Hsu CH, Li CY, Wang SC, Chen YH, Chang CR, Lee TY, Liu YR, Huang CY, Wu SH, Liu WL*, Liu PL* (2024 May). Curcumin regulates pulmonary extracellular matrix remodeling and mitochondrial function to attenuate pulmonary fibrosis by regulating the miR-29a-3p/DNMT3A axis. Biomedicine & Pharmacotherapy, 174, 116572. (2023 JCR IF: 6.9; 15/354, 4.2% in Pharmacology & Pharmacy) 本人為通訊作者.

3.          Yazal T, Lee PY, Chen PR, Chen IC, Liu PL, Chen YR, Lin TC, Chen YT, Huang SP, Yeh HC, Liu CC, Lo J, Wu HE, Wang SC, Li CY* (2023 Nov). Kurarinone exerts anti-inflammatory effect via reducing ROS production, suppressing NLRP3 inflammasome, and protecting against LPS-induced sepsis. Biomedicine & Pharmacotherapy, 167, 115619. (2023 JCR IF: 6.9; 15/354, 4.2% in Pharmacology & Pharmacy)

4.          Lo J, Wu HE, Liu CC, Chang KC, Lee PY, Liu PL, Huang SP, Wu PC, Lin TC, Lai YH, Chang YC, Chen YR, Lee SI, Huang YK, Wang SC, Li CY* (2023 Apr). Nordalbergin Exerts Anti-Neuroinflammatory Effects by Attenuating MAPK Signaling Pathway, NLRP3 Inflammasome Activation and ROS Production in LPS-Stimulated BV2 Microglia. International Journal of Molecular Sciences, 24, 7300. (2023 JCR IF: 4.9; 66/313, 21.1% in Biochemistry & Molecular Biology)

5.          Liu IF, Lin TC, Wang SC, Yen CH, Li CY, Kuo HF, Hsieh CC, Chang CY, Chang CR, Chen YH, Liu YR, Lee TY, Huang CY, Hsu CH*, Lin SJ*, and Liu PL* (2023 Mar). Long-term administration of Western diet induced metabolic syndrome in mice and causes cardiac microvascular dysfunction, cardiomyocyte mitochondrial damage, and cardiac remodeling involving caveolae and caveolin-1 expression. Biol Direct, 18, 9. (2023 JCR IF: 5.7; 10/109, 9.2% in Biology) 本人為通訊作者.

6.          Lai YH, Liu WL, Lee TY, Kuo CW, Liu YR, Huang CY, Chen YH, Chen IL, Wu SH, Wang SC, Lee PY, Liu CC, Lo J, Chang YC, Kuo HF, Hsieh CC, Li CY*, Liu PL* (2023, Feb). Magnolol regulates miR-200c-3p to inhibit epithelial–mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo. Phytomedicine, 154597. (2023 JCR IF: 6.7; 2/43, 4.7% in Integrative & Complementary Medicine) 本人為通訊作者.

7.          Chen YR, Wang SC, Huang SP, Su CC, Liu PL, Cheng WC, Chuu CP, Chen JK, Bao BY, Lee CH, Ke CC, Wu HE, Chang HH, Yeh HC*, Li CY* (2022, Dec). Protodioscin inhibits bladder cancer cell migration and growth, and promotes apoptosis through activating JNK and p38 signaling pathways. Biomedicine & pharmacotherapy, 156, 113929. (2023 JCR IF: 6.9; 15/354, 4.2% in Pharmacology & Pharmacy)

8.          Lo J, Liu CC, Li YS, Lee PY, Liu PL, Wu PC, Lin TC, Chen CS, Chiu CC, Lai YH, Chang YC, Wu HE, Chen YR, Huang YK, Huang SP, Wang SC, Li CY* (2022, Sep). Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. Journal of inflammation research, 15, 5347-5359. (2023 JCR IF: 4.2; 73/181, 40.3% in immunology)

9.          Chen SJ, Dalanbaatar S, Chen HY, Wang SJ, Lin WY, Liu PL, Tsai MY, Chen DC, Chen YH*, Chen WC* (2022, Aug). Astragalus membranaceus Extract Prevents Calcium Oxalate Crystallization and Extends Lifespan in a Drosophila Urolithiasis Model. Life (Basel), 12, 1250. (2023 JCR IF: 3.2; 26/109, 23.9% in Biology)

10.      Yeh HC, Su CC, Wu YH, Lee CH, Bao BY, Cheng WC, Wang SC, Liu PL, Chiu CC, Chuu CP, Ke CC, Wu HE, Chen YR, Chung WJ, Huang SP*, Li CY* (2022, May). Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer. European journal of pharmacology, 923, 174929. (2023 JCR IF: 4.2; 75/354, 21.2% in Pharmacology & Pharmacy)

11.      Kuo HF, Liu IF, Li CY, Tsai CS, Chen YH, Lian WS, Lin TC, Liu YR, Lee TY, Huang CY, Hsieh CC*, Hsu CH*, Lin FY*, Liu PL* (2021, Oct). Endocardial Endothelial Dysfunction and Unknown Polymorphic Composite Accumulation in Heart Failure. Biomedicines, 9, 1465. (2023 JCR IF: 3.9; 85/354, 24.0% in Pharmacology & Pharmacy) 本人為通訊作者.

12.      Chen IC, Wang SC, Chen YT, Tseng HH, Liu PL, Lin TC, Wu HE, Chen YR, Tseng YH, Hsu JH, Dai ZK, Suen JL*, Li CY* (2021, Oct). Corylin Ameliorates LPS-Induced Acute Lung Injury via Suppressing the MAPKs and IL-6/STAT3 Signaling Pathways. Pharmaceuticals, 14, 1046. (2023 JCR IF: 4.3; 69/354, 19.5% in Pharmacology & Pharmacy)

13.      Lee PY, Lai YH, Liu PL, Liu CC, Su CC, Chiu FY, Cheng WC, Hsu SL, Cheng KC, Chiu LY, Kao TE, Lin CC, Chang YC, Wang SC, Li CY* (2021, Sep). Toxicity of amantadine hydrochloride on cultured bovine cornea endothelial cells. Scientific reports, 11, 18514. (2023 JCR IF: 3.8; 25/134, 18.7% in Multidisciplinary Sciences)

14.      Hsu CH, Liu IF, Kuo HF, Li CY, Lian WS, Chang CY, Chen YH, Liu WL, Lu CY, Liu YR, Lin TC, Lee TY, Huang CY, Hsieh CC*, Liu PL* (2021, Sep). miR-29a-3p/THBS2 Axis Regulates PAH-induced Cardiac Fibrosis. International Journal of Molecular Sciences, 22, 10574. (2023 JCR IF: 4.9; 66/313, 21.1% in Biochemistry & Molecular Biology) 本人為通訊作者.

15.      Liu WL, Li CY, Cheng WC, Chang CY, Chen YH, Lu CY, Wang SC, Liu YR, Cheng MH*, Chong IW*, Liu PL* (2021, Mar). High Mobility Group Box 1 Promotes Lung Cancer Cell Migration and Motility via Regulation of Dynamin-Related Protein 1. International journal of molecular sciences, 22, 3628. (2023 JCR IF: 4.9; 66/313, 21.1% in Biochemistry & Molecular Biology) 本人為通訊作者.

16.      Lai YH, Lee PY, Lu CY, Liu YR, Wang SC, Liu CC, Chang YC, Chen YH, Su CC, Li CY, Liu PL* (2021, Jan). Thrombospondin 1-induced exosomal proteins attenuate hypoxia-induced paraptosis in corneal epithelial cells and promote wound healing. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 35, e21200. (2023 JCR IF: 4.4; 15/109, 13.8% in Biology) 本人為通訊作者.

17.      Hsieh CC, Li CY, Hsu CH, Chen HL, Chen YH, Liu YP, Liu YR, Kuo HF*, Liu PL* (2019, Jun). Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure. British journal of pharmacology, 176, 3791-3804. (2023 JCR IF: 6.8; 18/354, 5.1% in Pharmacology & Pharmacy) 本人為通訊作者.

18.      Kuo HF, Hsieh CC, Wang SC, Chang CY, Hung CH, Kuo PL, Liu YR, Li CY*, Liu PL* (2019, Jun). Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion. Journal of clinical medicine, 8, 794. (2023 JCR IF: 3.0; 59/329, 17.9% in Medicine, General & Internal) 本人為通訊作者.

19.      Huang WT, Chong IW, Chen HL, Li CY, Hsieh CC, Kuo HF, Chang CY, Chen YH, Liu YP, Lu CY, Liu YR, Liu PL* (2019, Feb). Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1. Cancer Letters, Volume 442, 2019, Pages 287-298. (2023 JCR IF: 9.1; 33/322, 10.2% in Oncology) 本人為通訊作者.

研究計畫

1.          科技部: 探討粒線體透過遷移體與隧道奈米管運輸與在抗腫瘤治療上的潛力與運用(NSTC-113-2314-B-037-078 )，期限: 2024/0801~2025/0731

2.          前瞻: 探討miR-19a-3p/POSTN軸調節ARDS衍生之肺纖維化於臨床治療上的潛力與運用(KMU-DK(A)114002)，期限: 2025/0101~2025/1231

3.          前瞻: 探討粒線體透過隧道奈米管運輸在抗腫瘤治療上的潛力與運用(KMU-DK(A)113010)，期限: 2024/0101~2024/1231

4.          科技部: 探討厚朴酚衍生物透過調節表觀遺傳和粒線體功能來抑制野百合鹼所誘導的肺動脈高壓(NSTC112-2314-B-006-056-MY3)，期限: 2023/0801~2024/0731

5.          科技部: 探討厚朴酚與厚朴酚具粒線體標靶衍生物抑制博來黴素誘導肺纖維化的表關遺傳調控與逆轉肺纖維化的功效(NSTC 112-2320-B-037-024)，期限: 2023/0801~2024/0731

6.          前瞻: 探討代謝症候群所導致小鼠心臟微血管功能障礙、小窩和小窩蛋白-1表達、心肌線粒體損傷與心臟重塑(KMU-DK(A)112003)，期限: 2023/0101~2023/1231

7.          院內: 解析厚朴萃取物抗腫瘤機制及評估其對視網膜母細胞瘤的臨床治療潛力(KMUH111-1M40)，期限: 2023/0101~2023/1231

8.          院內: 開發具粒腺體靶定之厚朴酚藥物及評估其對非小細胞肺癌的臨床治療潛力(KMUH111-1R10)，期限: 2023/0101~2023/1231

9.          科技部: 解析和厚朴抗纖維化機制及評估其對成人呼吸窘迫症候群後肺纖維化的臨床治療潛力(MOST111-2314-B-030-008)，期限: 2022/0801~2023/0731

10.      科技部: 開發具粒線體靶定之厚朴酚藥物及評估其對非小細胞肺癌的臨床治療潛力(MOST111-2314-B-037-114)，期限: 2022/0801~2023/0731

11.      前瞻: 探討厚朴萃取物的抗肺纖維化機制與臨床治療應用(KMU-DK(A)111007)，期限: 2022/0101~2022/1231

12.      院內: 探討厚朴酚在視網膜母細胞瘤中的抗癌作用及其作用機制(KMUH110-0M48)，期限: 2022/0101~2022/1231

13.      科技部: 探討薑黃素調控miR-29a-3p的抗肺纖維化作用及其機制(MOST110-2314-B-037-125)，期限: 2021/0801~2022/0731

14.      科技部: 鳶尾素對減輕肺動脈高壓進展的調節機制(MOST109-2314-B-006-094-MY3)，期限: 2020/0801~2021/0731

15.      科技部: 高遷移率族蛋白1透過調控粒線體功能與促進肺癌轉移(MOST109-2314-B-030-002-MY2)，期限: 2020/0201~2021/0731

16.      科技部: 高遷移率族蛋白透過調控發炎體與細胞焦亡促進肺癌轉移(MOST108-2314-B-037-093-MY3)，期限: 2020/0801~2021/0731

專利

1.      美國: DR20：A NOVEL ANTI-FIBROTIC, ANTI-CANCER, ANTI-PAH THERAPIES DRUG(63/716, 785)，劉博侖、林韋佑、郭炫孚、鄭孟軒

2.      美國: 用於促進皮膚細胞增生及／或遷移的組成物、生薑萃取物及其醫藥組成物(8,772,347)，王惠民、陳中一、邱建志、周怡廷、劉博侖

3.      中華民國: 具雙影像追蹤探針之高分子奈米載體及其製備方法(I530296)，王志光、潘力誠、李之昀、林宏哲、林哲緯、劉博侖、史秉修

4.      中華民國: 用於促進皮膚細胞增生及/或遷移的組成物,生薑促取物及醫藥組成物(I446919)，王惠民、陳中一、邱建志、周怡廷、劉博侖